文献速递妇科肿瘤

戈沙妥珠单抗在晚期实体瘤患者中的疗效与安全性(TROPiCS-03):晚期子宫内膜癌患者分析

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.
PubMed 文献 · J Clin Oncol · 2024-07-31

TROPiCS-03是一项多队列、开放标签、II期篮子研究,评估戈沙妥珠单抗(SG)在晚期子宫内膜癌(EC)患者中的疗效与安全性。41例患者接受SG 10 mg/kg(第1、8天,每3周一次),客观缓解率(ORR)为22%(95% CI 11-38),临床获益率(CBR)为32%(95% CI 18-48),中位无进展生存期(PFS)为4.8个月(95% CI 2.8-9.8)。≥3级治疗相关不良事件(TRAE)发生率为73%,因TRAE停药率为5%。

要点

  • SG在经多线治疗的晚期EC患者中ORR为22%(95% CI 11-38),CBR为32%(95% CI 18-48)。
  • 中位缓解持续时间(DOR)为8.8个月(95% CI 2.8-不可估计),中位PFS为4.8个月(95% CI 2.8-9.8)。
  • ≥3级TRAE发生率为73%,因TRAE停药率为5%,2例死亡判定与SG无关。

核心结论

  • TROPiCS-03研究显示SG在经多线治疗的晚期EC患者中具有令人鼓舞的疗效,毒性谱可控,安全性特征与已知SG安全性谱一致。

研究设计与样本

  • TROPiCS-03(ClinicalTrials.gov标识符:NCT03964727)是一项在转移性实体瘤患者中开展的多队列、开放标签、II期篮子研究。
  • EC队列纳入41例患者,接受SG 10 mg/kg,第1天和第8天给药,每3周一次。
  • 主要终点为研究者按RECIST v1.1评估的客观缓解率(ORR);次要终点包括临床获益率(CBR)、缓解持续时间(DOR)、无进展生存期(PFS)、总生存期和安全性。
  • 对存档或基线肿瘤标本进行Trop-2免疫组化表达分析。

主要发现

  • 数据提取时共纳入41例患者,中位随访时间为5.8个月(范围0.7-19.3),中位既往治疗线数为3线(范围1-6),85%的患者既往接受过化疗和免疫治疗。
  • ORR为22%(95% CI 11-38),CBR为32%(95% CI 18-48)。
  • 中位DOR为8.8个月(95% CI 2.8-不可估计),中位PFS为4.8个月(95% CI 2.8-9.8)。
  • 对39例患者进行了回顾性Trop-2探索性分析,肿瘤Trop-2蛋白在EC中高表达,与疗效的相关性有限。
  • ≥3级治疗相关不良事件(TRAE)发生率为73%,因TRAE停药率为5%,发生2例死亡,判定与SG无关。

局限性

  • Trop-2探索性分析为回顾性分析,仅对39例患者进行。
  • 样本量较小(41例),随访时间较短(中位5.8个月,范围0.7-19.3)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with advanced endometrial cancer (EC) who progress on or after platinum-based therapy and immunotherapy have poor prognosis. We report efficacy and safety of sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug conjugate, in patients with advanced EC. METHODS: TROPiCS-03 (ClinicalTrials.gov identifier: NCT03964727) is a multicohort, open-label, phase II basket study in patients with metastatic solid tumors. Eligible patients in the EC cohort received SG 10 mg/kg once on days 1 and 8 every 3 weeks. Primary end point was objective response rate (ORR) by investigator's assessment per RECIST v1.1. Secondary end points included clinical benefit rate (CBR; complete and partial response, and stable disease ≥6 months), duration of response (DOR), and progression-free survival (PFS) per investigator assessment, overall survival, and safety. Trop-2 expression of archival or baseline tumor specimens was analyzed by immunohistochemistry. RESULTS: At data extraction date, 41 patients were enrolled. Median follow-up was 5.8 months (range, 0.7-19.3); median previous therapies was three (range, 1-6); and 85% of patients received previous chemotherapy and immunotherapy. ORR was 22% (95% CI, 11 to 38); CBR was 32% (95% CI, 18 to 48). Median DOR was 8.8 months (95% CI, 2.8 to not estimable); median PFS was 4.8 months (95% CI, 2.8 to 9.8). Trop-2 exploratory analysis was conducted retrospectively for 39 patients. Tumor Trop-2 protein was highly expressed in EC, showing limited correlation with efficacy. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 73% of patients. Study drug discontinuation due to TRAEs was 5%. Two deaths occurred, deemed unrelated to SG. CONCLUSION: Findings from TROPiCS-03 showed encouraging efficacy of SG with a manageable toxicity profile in a heavily pretreated population with advanced EC. Safety findings were consistent with the known SG safety profile.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Santin AD, Corr BR, Spira A, et al. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2024. PMID: 39083724. doi:10.1200/JCO.23.02767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。